24 results on '"Nilsson S"'
Search Results
2. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
3. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
4. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
5. Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
6. Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)
7. Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
8. Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
9. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)
10. 824P - Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
11. 778TiP - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)
12. 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
13. External-Beam Radiation Therapy (Ebrt) Use and Safety with Radium-223 Dichloride (Ra) in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases (Mets) from the Alsympca Trial
14. 1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles
15. Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets)
16. 751P - Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
17. 750P - Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
18. C19 - Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP)
19. Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)
20. A Prostate Cancer Expression Signature to Predict Survival Benefit of Primary Hormone Therapy
21. Safety of Cytotoxic Chemotherapy Following Radium-223 Chloride (RA-223) Therapy in the Phase 3 Alsympca Study in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
22. 768P - External-Beam Radiation Therapy (Ebrt) Use and Safety with Radium-223 Dichloride (Ra) in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases (Mets) from the Alsympca Trial
23. 770P - Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets)
24. 769P - 1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.